Dragonfly Therapeutics
Dragonfly Therapeutics is a clinical-stage biotech company dedicated to revolutionizing disease treatment by inventing natural killer cell-based therapies. They focus on autoimmune disease, oncology, fibrosis, neuro-inflammation, neurology, and beyond, building drugs with proprietary platforms TriNKET® and CYTOKINE. Their mission is to harness the power of the immune system for vastly improved patient outcomes. The company was launched in 2016 by leading figures in disease biology and immunology, including Tyler Jacks, Bill Haney, and David Raulet, with a scientific advisory board comprising Nobel laureates and world-class experts in immunology and cancer biology. Their therapies are designed to be potent as single agents and in combination with existing treatments, aiming to provide breakthrough therapies for patients.
Industries
Nr. of Employees
medium (51-250)
Dragonfly Therapeutics
180 3rd Avenue, Sixth Floor, Waltham, MA 02451, United States
Patents
Multi-specific binding proteins that bind HER2, NKG2D, and CD16, and methods of use
US-12275791-B2
View DetailsMulti-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use
US-12215157-B2
View Details
Multi-specific binding proteins that bind HER2, NKG2D, and CD16, and methods of use
US-12275791-B2
View DetailsMulti-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use
US-12215157-B2
View DetailsProducts
HER2‑targeting tri‑specific NK/T cell engager (clinical‑stage)
A multi‑specific engager designed to redirect NK cells and CD8+ T cells to HER2‑expressing tumors; evaluated in early‑phase clinical studies as monotherapy and in combination with antibody–drug conjugates and checkpoint inhibitors.
EGFR‑targeting tri‑specific NK cell engager (clinical‑stage)
A multi‑specific engager directing NK cell activity to EGFR‑expressing tumors; developed for solid tumor indications and evaluated in combination with checkpoint inhibitors.
Engineered IL‑2‑based cytokine agonist (clinical‑stage)
An engineered IL‑2 cytokine with modified receptor activity designed to increase therapeutic index and demonstrate efficacy alone and in combination with PD‑1 pathway blockade in preclinical and early clinical studies.
IL‑12 Fc‑fusion cytokine with extended half‑life (clinical‑stage / licensed)
An Fc‑fusion cytokine engineered to prolong circulation and modulate the tumor microenvironment to increase inflammatory anti‑tumor responses; subject to partner licensing arrangements.
Portfolio of partner‑licensed multi‑specific engager candidates
Multiple multi‑specific engager candidates that have been optioned or licensed to external pharmaceutical partners for further development across oncology and related indications.
HER2‑targeting tri‑specific NK/T cell engager (clinical‑stage)
A multi‑specific engager designed to redirect NK cells and CD8+ T cells to HER2‑expressing tumors; evaluated in early‑phase clinical studies as monotherapy and in combination with antibody–drug conjugates and checkpoint inhibitors.
EGFR‑targeting tri‑specific NK cell engager (clinical‑stage)
A multi‑specific engager directing NK cell activity to EGFR‑expressing tumors; developed for solid tumor indications and evaluated in combination with checkpoint inhibitors.
Engineered IL‑2‑based cytokine agonist (clinical‑stage)
An engineered IL‑2 cytokine with modified receptor activity designed to increase therapeutic index and demonstrate efficacy alone and in combination with PD‑1 pathway blockade in preclinical and early clinical studies.
IL‑12 Fc‑fusion cytokine with extended half‑life (clinical‑stage / licensed)
An Fc‑fusion cytokine engineered to prolong circulation and modulate the tumor microenvironment to increase inflammatory anti‑tumor responses; subject to partner licensing arrangements.
Portfolio of partner‑licensed multi‑specific engager candidates
Multiple multi‑specific engager candidates that have been optioned or licensed to external pharmaceutical partners for further development across oncology and related indications.
Services
Co‑development agreements and research collaborations to discover, preclinically characterize, and advance therapeutic candidates into clinical development with external partners.
Negotiation and execution of licensing transactions, option agreements, and milestone/royalty arrangements for clinical‑stage and preclinical candidates to enable partner‑led development.
Co‑development agreements and research collaborations to discover, preclinically characterize, and advance therapeutic candidates into clinical development with external partners.
Negotiation and execution of licensing transactions, option agreements, and milestone/royalty arrangements for clinical‑stage and preclinical candidates to enable partner‑led development.
Expertise Areas
- NK cell engager immunotherapy
- Engineered cytokines and Fc‑fusion biologics
- Protein and ligand engineering with structural guidance
- Immuno‑oncology and combination therapy development
Key Technologies
- Multi‑specific immune engagers (tri‑/multi‑specific formats)
- Engineered cytokines and Fc‑fusion proteins
- Protein engineering and ligand design
- Structural biology of receptor–ligand interactions
News & Updates
DRAGONFLY's mission is to revolutionize disease treatment by inventing natural killer cell-based therapies for vastly improved patient outcomes. They build drugs in autoimmune disease, oncology, fibrosis, neuro-inflammation, neurology, and beyond, in collaboration with partners like AbbVie, BMS, Gilead, and Merck. They have generated 11 drug candidates handed off to partners.
Dragonfly will deliver poster presentations at the Society for Immunotherapy of Cancer (SITC) Annual Conference, highlighting preclinical data supporting assets DF6215, an engineered IL-2 cytokine, and DF9001, an EGFR-targeting TriNKET, for the treatment of advanced solid tumors.
The publication titled 'An optimized IL-12 cytokine' supports the potential of DF6002 as a cancer treatment.
Bristol Myers Squibb exercised its option for a TriNKET candidate, marking the first outside of oncology, and Dragonfly will receive a $25 million payment.
The first TriNKET, HER2-targeting DF1001, entered Phase 2. The Phase 1 study showed tolerability and encouraging effects.
Gilead Sciences and Dragonfly announced a collaboration to develop NK cell engagers for cancer, infectious diseases, and immune disorders.
DRAGONFLY's mission is to revolutionize disease treatment by inventing natural killer cell-based therapies for vastly improved patient outcomes. They build drugs in autoimmune disease, oncology, fibrosis, neuro-inflammation, neurology, and beyond, in collaboration with partners like AbbVie, BMS, Gilead, and Merck. They have generated 11 drug candidates handed off to partners.
Dragonfly will deliver poster presentations at the Society for Immunotherapy of Cancer (SITC) Annual Conference, highlighting preclinical data supporting assets DF6215, an engineered IL-2 cytokine, and DF9001, an EGFR-targeting TriNKET, for the treatment of advanced solid tumors.
The publication titled 'An optimized IL-12 cytokine' supports the potential of DF6002 as a cancer treatment.
Bristol Myers Squibb exercised its option for a TriNKET candidate, marking the first outside of oncology, and Dragonfly will receive a $25 million payment.
The first TriNKET, HER2-targeting DF1001, entered Phase 2. The Phase 1 study showed tolerability and encouraging effects.
Gilead Sciences and Dragonfly announced a collaboration to develop NK cell engagers for cancer, infectious diseases, and immune disorders.